Immuno-oncology: Is it a New Hope for Cancer Patients
DOI:
https://doi.org/10.17140/CSMMOJ-2-108Abstract
Cancer is the one of the leading causes of death, whose incidences is increasing day by day due to lack of understanding about its complete mechanism. Therefore, to understand complete mechanism of cancer, researchers started to move their focus from the cancer cell to the host and the environment in which the cancer grows, a very important component of which is the immune system.1,2 The immune system comprises of innate and adaptive system which provides protection to the body against pathogens. The immune cell receptors recognize the foreign and activate the complex immune response signaling pathways which results in the elimination of pathogens.3,4 The first problem with cancer cells is that they arise from our own cells, so some times unable to recognize as non self. Further, if they recognized, alters the immune response signaling pathways at various steps which results in failure of immune response. The cancer cells can avoid recognition and elimination by altering the immune response signaling pathways at various steps such as disrupting antigen recognition and presentation mechanisms, down regulates the MHC class I molecules or inhibiting the antigen processing mechanisms. Additionally, cancer cells may disrupt the pathways which are involved in controlling T-cell inhibition and activation, or by recruiting regulatory T cells (Treg) and Myeloid-derived suppressor cells (MDSC) which are immunosuppressive. Further, cancer cells may release of some of immunosuppressive immune factors such as adenosine and prostaglandin E2, and the enzyme Indoleamine 2,3-dioxygenase (IDO) which leads to progression of cancer.
References
Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Annals of on-col. 2012; 23: 86-89. doi: 10.1093/annonc/mds256
Chen DS, Mellman I. Oncology meets immunology: the can-cerimmunity cycle. Immunity. 2013; 39: 1-10. doi: 10.1016/j. immuni.2013.07.012
Kumar A, Sharma N, Singh S, Sasmal D, Dev A. Oral vaccine antigen induced immune response signalling pathways: current and future perspectives. J. vaccine and vaccination. 2014; 5: 2-6. doi: 10.4172/2157-7560.1000225
Kumar A, Sasmal D, Sharma N. Understanding of complex signaling pathways of immune system: a review. World journal of pharmacy and pharmaceutical sci. 2014; 3: 241-255.
Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994; 180: 1-4.
Janeway CA, Travers P, Walport M. Immunobiology: the im-mune system in health and disease. New York, NY: Current Bi-ology Publications; 1999.
De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nature reviews cancer. 2006; 6: 24-37.
Parish CR. Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol. 2003; 81: 106-113. doi: 10.1046/j.0818-9641.2003.01151.x
Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. Jour-nal of Clinical Oncology. 2004; 22: 1136-1151. doi: 10.1200/ JCO.2004.10.041
Lu H. TLR agonists for cancer immunotherapy: tip-ping the balance between the immune stimulatory and inhibi-tory effects. Frontiers in immunol. 2014: 5. doi: 10.3389/fim-mu.2014.00083
Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer thera-py. Oncoimmunol. 2012; 1: 894-907. doi: 10.4161/onci.20931
Krieg AM. Tolllike receptor 9 (TLR9) agonists in the treat-ment of cancer. Oncogene. 2008; 27: 161-167. doi: 10.1038/ sj.onc.1210911
Gubin MM, Zhang X, Schuster H, et al. Checkpoint block-ade cancer immunotherapy targets tumour-specific mutant an-tigens. Nature. 2014; 515: 577-581. doi: 10.1038/nature13988
Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PDL1) treatment leads to clinical activity in metastatic blad-dercancer.Nature.2014; 515: 558-562. doi: 10.1038/nature13904
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Na-ture. 2014; 515: 568-571. doi: 10.1038/nature13954
Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: combination strategies for cancer therapy. Na-ture Reviews Drug Discovery. 2008; 7: 231-240. doi: 10.1038/ nrd2482
Rosenberg SA, Yang JC, Restifo NP. Cancer immunothera-py: moving beyond current vaccines. Nature medicine. 2004; 10: 909-915. doi: 10.1038/nm1100
Markley JC, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cellmediated rejection of sys-temic lymphoma in immunodeficient mice. Blood. 2010; 115: 3508-3519. doi: 10.1182/blood-2009-09-241398
Liu S, Lizée G, Lou Y, et al. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. International immunol. 2007; 19: 1213-1221. doi: 10.1093/ intimm/dxm093
Kalos M, June CH. Adoptive T cell transfer for cancer im-munotherapy in the era of synthetic biology. Immunity. 2013; 39: 49-60. doi: 10.1016/j.immuni.2013.07.002
Restifo NP, Dudley ME, Rosenberg SA. Adoptive immuno-therapy for cancer: harnessing the T cell response. Nature Re-views Immunol. 2012; 12: 269-281. doi: 10.1038/nri3191 Cancer Stud Mol Med Open J
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.